| 前收盘价格 | 21.71 |
| 收盘价格 | 21.94 |
| 成交量 | 2,542,744 |
| 平均成交量 (3个月) | 2,815,493 |
| 市值 | 2,062,079,744 |
| 价格/销量 (P/S) | 3.35 |
| 股市价格/股市净资产 (P/B) | 247.70 |
| 52周波幅 | |
| 利润日期 | 5 May 2026 |
| 营业毛利率 | -93.04% |
| 营业利益率 (TTM) | -102.62% |
| 稀释每股收益 (EPS TTM) | -5.83 |
| 季度收入增长率 (YOY) | 28.00% |
| 总债务/股东权益 (D/E MRQ) | 588.24% |
| 流动比率 (MRQ) | 2.40 |
| 营业现金流 (OCF TTM) | -389.94 M |
| 杠杆自由现金流 (LFCF TTM) | -172.94 M |
| 资产报酬率 (ROA TTM) | -24.51% |
| 股东权益报酬率 (ROE TTM) | -377.06% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Ultragenyx Pharmaceutical Inc. | 看跌 | 看跌 |
AIStockmoo 评分
1.7
| 分析师共识 | 4.0 |
| 内部交易活动 | 1.0 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.70 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.20% |
| 机构持股比例 | 99.43% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sands Capital Management, Llc | 31 Dec 2025 | 3,485,724 |
| Rtw Investments, Lp | 31 Dec 2025 | 3,000,139 |
| Baker Bros. Advisors Lp | 31 Dec 2025 | 2,772,692 |
| Frontier Capital Management Co Llc | 31 Dec 2025 | 1,965,084 |
| Bnp Paribas Asset Management Holding S.A. | 31 Dec 2025 | 1,899,661 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 79.00 (Canaccord Genuity, 270.20%) | 购买 |
| 中 | 51.00 (138.99%) | |
| 低 | 25.00 (Wedbush, 17.15%) | 保留 |
| 平均值 | 52.30 (145.08%) | |
| 总计 | 9 购买, 1 保留 | |
| 平均价格@调整类型 | 21.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 18 Feb 2026 | 79.00 (270.20%) | 购买 | 20.45 |
| Evercore ISI Group | 18 Feb 2026 | 34.00 (59.33%) | 购买 | 20.45 |
| 17 Feb 2026 | 37.00 (73.38%) | 购买 | 20.18 | |
| HC Wainwright & Co. | 17 Feb 2026 | 50.00 (134.30%) | 购买 | 20.18 |
| 03 Feb 2026 | 60.00 (181.16%) | 购买 | 24.80 | |
| Wedbush | 17 Feb 2026 | 25.00 (17.15%) | 保留 | 20.18 |
| Guggenheim | 05 Jan 2026 | 52.00 (143.67%) | 购买 | 23.11 |
| B of A Securities | 02 Jan 2026 | 58.00 (171.79%) | 购买 | 23.60 |
| Baird | 30 Dec 2025 | 47.00 (120.24%) | 购买 | 22.78 |
| Jefferies | 30 Dec 2025 | 63.00 (195.22%) | 购买 | 22.78 |
| Leerink Partners | 30 Dec 2025 | 70.00 (228.02%) | 购买 | 22.78 |
| Wells Fargo | 30 Dec 2025 | 45.00 (110.87%) | 购买 | 22.78 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CROMBEZ ERIC | 23.39 | 23.02 | 4,614 | 110,522 |
| HARRIS ERIK | 23.39 | 23.02 | 1,104 | 29,722 |
| HORN HOWARD | 23.39 | 22.55 | -3,901 | -85,975 |
| HUANG DENNIS KARL | 23.39 | 23.02 | 10,138 | 237,497 |
| HUIZENGA THEODORE ALAN | - | 23.02 | -1,780 | -40,976 |
| KAKKIS EMIL D | 23.39 | 23.02 | 16,773 | 412,450 |
| PARSCHAUER KARAH HERDMAN | 23.39 | 22.37 | -6,524 | -134,778 |
| PINION JOHN RICHARD | 23.39 | 23.02 | 1,108 | 29,627 |
| 累积净数量 | 21,532 | |||
| 累积净值 ($) | 558,089 | |||
| 累积平均购买 ($) | 23.39 | |||
| 累积平均卖出 ($) | 22.78 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PARSCHAUER KARAH HERDMAN | 职员 | 10 Mar 2026 | 卖 (-) | 3,508 | 22.84 | 80,123 |
| PARSCHAUER KARAH HERDMAN | 职员 | 06 Mar 2026 | 卖 (-) | 6,018 | 21.25 | 127,883 |
| HORN HOWARD | 职员 | 03 Mar 2026 | 卖 (-) | 1,635 | 22.07 | 36,084 |
| HUANG DENNIS KARL | 职员 | 02 Mar 2026 | 处理 (-) | 999 | 23.02 | 22,997 |
| CROMBEZ ERIC | 职员 | 02 Mar 2026 | 卖 (-) | 7,029 | 23.02 | 161,808 |
| HORN HOWARD | 职员 | 02 Mar 2026 | 卖 (-) | 8,409 | 23.02 | 193,575 |
| HUIZENGA THEODORE ALAN | 职员 | 02 Mar 2026 | 处理 (-) | 148 | 23.02 | 3,407 |
| HUIZENGA THEODORE ALAN | 职员 | 02 Mar 2026 | 卖 (-) | 1,632 | 23.02 | 37,569 |
| PARSCHAUER KARAH HERDMAN | 职员 | 02 Mar 2026 | 卖 (-) | 8,135 | 23.02 | 187,268 |
| KAKKIS EMIL D | 职员 | 02 Mar 2026 | 卖 (-) | 54,404 | 23.02 | 1,252,380 |
| HARRIS ERIK | 职员 | 02 Mar 2026 | 卖 (-) | 10,539 | 23.02 | 242,608 |
| PINION JOHN RICHARD | 职员 | 02 Mar 2026 | 卖 (-) | 10,029 | 23.02 | 230,868 |
| HUANG DENNIS KARL | 职员 | 01 Mar 2026 | 获得 (+) | 11,137 | 23.39 | 260,494 |
| CROMBEZ ERIC | 职员 | 01 Mar 2026 | 获得 (+) | 11,643 | 23.39 | 272,330 |
| HORN HOWARD | 职员 | 01 Mar 2026 | 获得 (+) | 6,143 | 23.39 | 143,685 |
| PARSCHAUER KARAH HERDMAN | 职员 | 01 Mar 2026 | 获得 (+) | 11,137 | 23.39 | 260,494 |
| KAKKIS EMIL D | 职员 | 01 Mar 2026 | 获得 (+) | 71,177 | 23.39 | 1,664,830 |
| HARRIS ERIK | 职员 | 01 Mar 2026 | 获得 (+) | 11,643 | 23.39 | 272,330 |
| PINION JOHN RICHARD | 职员 | 01 Mar 2026 | 获得 (+) | 11,137 | 23.39 | 260,494 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合